...
首页> 外文期刊>Journal of Clinical Microbiology >Emergence of Multidrug Resistance in Ubiquitous and Dominant Pseudomonas aeruginosa Serogroup O:11
【24h】

Emergence of Multidrug Resistance in Ubiquitous and Dominant Pseudomonas aeruginosa Serogroup O:11

机译:遍在和优势的铜绿假单胞菌血清群O:11的多药耐药性的出现

获取原文
           

摘要

The serotypes of 88 nonreplicate nosocomial Pseudomonas aeruginosa isolates from 11 Greek hospitals were studied in relation to their antibiotic susceptibilities. Rates of resistance to β-lactams, aminoglycosides, and quinolones ranged from 31 to 65%, except for those to ceftazidime (15%) and imipenem (21%). Four serotypes were dominant: O:12 (25% of isolates), O:1 (17%), O:11 (16%), and O:6 (10%). Multidrug resistance rates in the major serogroups O:12 (91%) and O:11 (79%) were higher than those in serogroups O:1 (40%) and O:6 (43%). Further typing with respect to pulsed-field gel electrophoresis patterns following XbaI digestion of genomic DNA discriminated the isolates into 74 types. Pulsed-field gel electrophoresis revealed that the ubiquitous O:12 group was genetically homogeneous, since 95% of strains belonged to two clusters of genotypic similarity, while the O:11 strains, present in 8 of the 11 hospitals, were distributed among five such clusters. Therefore, apart from the already reported O:12 multidrug-resistant European clone, an O:11 population, characterized by a serotype known to be dominant in the environment and the hospital in several parts of the world, but previously not associated with multidrug resistance to antibiotics, has progressed to a multidrug-resistant state.
机译:研究了来自希腊11家医院的88例非复制型医院内铜绿假单胞菌(Pseudomonas aeruginosa )分离株的血清型及其药敏性。除对头孢他啶(15%)和亚胺培南(21%)的抗性外,对β-内酰胺类,氨基糖苷类和喹诺酮类药物的耐药率范围为31%至65%。四种血清型占优势:O:12(占分离株的25%),O:1(占17%),O:11(占16%)和O:6(占10%)。主要血清组O:12(91%)和O:11(79%)的多药耐药率高于O:1(40%)和O:6(43%)的血清群。基因组DNA的 Xba 消化后,根据脉冲场凝胶电泳图谱的进一步分类将分离物分为74种。脉冲场凝胶电泳显示,普遍存在的O:12组在基因上是同质的,因为95%的菌株属于两类基因型相似性,而11家医院中的8家中存在的O:11菌株则分布在五家这样的医院中集群。因此,除了已经报道的欧洲耐O:12的多药耐药克隆外,O:11人群的特征是血清型在世界各地都在环境和医院中占主导地位,但以前与耐多药性无关对抗生素而言,已发展成一种多药耐药状态。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号